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Abstract: Muscle weakness and associated diseases are likely to place a considerable economic 
burden on government health care expenditure. Therefore, our aim for this study was to estimate 
the direct and indirect costs associated with muscle weakness in the Czech Republic. We applied 
a cost-of-illness approach using data from the Survey of Health, Ageing and Retirement in Europe 
(SHARE). Six hundred and eighty-nine participants aged 70 years and over and without any long-
term illnesses were included in our study. A generalized linear model with gamma distribution 
was used, and odds ratio (OR) was calculated in order to explore the effect of muscle weakness 
on direct and indirect costs. For both genders, muscle weakness had a statistically significant 
impact on direct costs (OR =2.11), but did not have a statistically significant impact on indirect 
costs (OR =1.08) or on total cost (OR =1.51). Muscle weakness had the greatest statistically 
significant impact on direct costs in females (OR =2.75). In conclusion, our study has shown 
that muscle weakness may lead to increased direct costs, and consequently place a burden on 
health care expenditure. Therefore, the results of this study could lead to greater interest in the 
prevention of muscle weakness among older people in the Czech Republic.
Keywords: direct cost, indirect cost, economic burden, sarcopenia, frailty
Introduction
Muscle weakness as a lack of muscle strength is a primary symptom of a variety of 
skeletal muscle diseases1 including frailty2 and sarcopenia,3,4 both of which have been 
linked to increased health care expenditure for older people.5–7 In particular, frailty and 
its comorbidities are associated with a greater use of hospital facilities and other health 
care resources.8 Muscle weakness is also a significant contributing factor for falls.9 
Hospitalization following a fall frequently results in further sarcopenia, often leading to 
a permanent loss of independence,10 in turn generating considerable treatment costs.
Studies carried out in the USA have shown that reducing the prevalence of sarcope-
nia by 10% would result in savings of $1.1 billion per year in US health care costs.7 
However, in the Czech Republic, the relationship between muscle weakness and health 
care costs has received little attention. Appropriate interventions such as physical 
exercise are known to lower the risk of developing sarcopenia and frailty, as well as 
muscle weakness,11 and hold promise for ameliorating the financial burden associated 
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with these conditions.12 Consequently, increased knowledge 
of the impact of muscle weakness on health care expenditure 
could bring support for the introduction of physical activity 
programs for older people in the Czech Republic. Therefore, 
the main aim of this study was to describe the influence of 
muscle weakness on health care expenditure in the Czech 
Republic. However, it should be noted that we have only 
included those participants without any long-term illnesses.
Methods
study population
This study used data from the Survey of Health, Age-
ing and Retirement in Europe (SHARE) Wave 6 (DOI: 
10.6103/SHARE.w6.600).13 See Börsch-Supan et al14 
for methodological details. The data accessed from SHARE 
are available to the scientific community after registering for 
free. No approval from an ethics committee or an institutional 
review board was required. Data from 750 participants 
without any long-term illnesses aged $70 from the Czech 
Republic were included in the study. After excluding all those 
with missing data in the variables which were included into 
the regression models, data from 689 participants were used 
for the analyses.
long-term illness
The SHARE survey determined the presence of any long-term 
illnesses using the following question: Some people suffer 
from chronic or long-term health problems. By chronic or 
long term, we mean it has troubled you over a period of time 
or is likely to affect you over a period of time. Do you have 
any such health problems, illness, disability or infirmity?
Muscle weakness
In accordance with suggested methods, we used a grip strength 
(GS) test to estimate muscle weakness.15 In SHARE, the GS 
was measured using a handheld dynamometer (Smedley, 
S Dynamometer, 100 kg; TTM, Tokyo, Japan). Participants 
were asked to squeeze the handle of the dynamometer as hard 
as they could for a couple of seconds and then let go. Two 
alternate measurements from their right and left hands were 
performed. The measurement was carried out in three posi-
tions in SHARE: lying, sitting and standing. For the purposes 
of this study, we only used data from participants who were 
measured in standing and sitting positions and from those 
who gave full effort without the support of the other hand. 
The maximum value was defined as the maximum perfor-
mance of the strongest hand.16 Muscle weakness was defined 
as low GS ,26 kg in men and ,16 kg in women.15
Cost of illness
We used a cost-of-illness approach to estimate the increase 
in expenditure associated with muscle weakness. This 
approach involved estimating the costs associated with the 
treatment and care of patients with any disease. The expen-
diture was divided into two important groups: direct and 
indirect costs.17,18 In this case, direct costs referred to the 
cost of medical care and medication. Indirect costs included 
the replacement cost. All figures could be obtained from the 
SHARE questionnaire.
Participants were asked how many times in total they had 
seen or talked to a medical doctor in the last year, including 
emergency room or outpatient clinic visits. They were then 
asked how many nights they had spent in hospital over the 
last 12 months. The average cost of hospital admission 
was 54.59 € per day, and the average cost of an ordinary 
visit to a medical specialist was 12.47 € per visit. These 
figures were obtained from official statistics published by 
the Ministry of Health in the Czech Republic. In the Czech 
Republic, health insurance covers the total medical-related 
costs incurred plus the cost of any out-of-pocket medications 
bought by the patient. The cost of out-of-pocket medications 
for patients was estimated using another question: Overall, 
approximately how much did you spend on your medication 
in the last 12 months (that is, how much did you pay without 
being reimbursed [by a health insurance/your national health 
system/a third-party payer])?
Additionally, we estimated indirect costs. In order to do 
so, we used a series of questions to enquire about the amount 
of help provided by a family member from outside the house-
hold or by any friend or neighbor. Using these questions, 
we were able to estimate the total time which all caregivers 
spent assisting participants. To estimate the replacement cost, 
we used the average wage of a professional caregiver in the 
Czech Republic (6.34 € per hour), which was obtained from 
the Ministry of Labour and Social Affairs.
statistical analysis
The means and standard deviations were calculated for 
continuous variables, whereas frequencies and percentages 
were calculated for categorical variables in the descriptive 
statistics. Differences between sample proportions of cat-
egorical variables were tested by a χ2 test (p,0.05). The 
nonparametric Mann–Whitney U test (p,0.05) was used to 
test for differences between groups according to the weakness 
status. A generalized linear model with gamma distribution 
was used to explore the effect of muscle weakness on each 
cost separately. All the models were adjusted for age and 
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Muscle weakness cost in the Czech republic
body mass index. Odds ratio (OR) was used as the main 
outcome of effect size in the generalized linear model. An OR 
value higher than 1 implies that muscle weakness caused the 
costs to be more expensive. All the statistical analyses were 
performed using IBM SPSS Statistics 22.
Results
Data from 304 men and 385 women were analyzed. The 
average age was 75.6±5.1. Participants diagnosed with 
muscle weakness (81.8±6.6) were significantly older than 
participants with normal muscle strength (75.2±4.8). With 
increasing age, the prevalence of muscle weakness also 
increased, from 4.6% for those aged 70–74 years old to 31.9% 
for participants over 85 years of age. Prevalence of muscle 
weakness in males was 8.6% and in females was 10.1%. 
The descriptive statistics of the study sample are presented 
in Table 1.
Direct, indirect and total costs were statistically higher 
for the muscle weakness group compared with the normal 
muscle group. In all the estimates, the hospital admission had 
a major contribution to the direct cost because the muscle 
weakness group was almost a third more likely to attend 
hospital admission. The average total cost was estimated 
at 1,125.3±1,367.2 € for the group with muscle weakness 
and 561.4±762.6 € per year for the normal muscle group. 
A summary of costs per year divided according to muscle 
weakness status is presented in Table 2.
Table 3 shows the results obtained from generalized 
linear regression models estimated separately for each type 
of cost. In both genders combined, muscle weakness had a 
statistically significant impact on direct costs (OR =2.11), 
but did not have a statistically significant impact on indirect 
costs (OR =1.08) or total cost (OR =1.51). In males, muscle 
weakness did not have a statistically significant impact on 
any of the costs. The highest statistically significant impact 
was found to be the impact of muscle weakness on direct 
costs in females (OR =2.75).
Discussion
According to our results, muscle weakness may influence 
health care expenditure for elderly people in the Czech 
Republic who are relatively healthy and do not have any 
long-term illnesses. In the context of previous studies, these 
results are not unexpected. Several diseases which are con-
nected with the musculoskeletal system have previously been 
found to increase health care expenditure. For example, Bock 
et al6 found that frailty is associated with increased health care 
costs among older Germans. Furthermore, frailty was shown 
to increase surgical hospital costs after colorectal operations 
in American older adults.19 In Ireland, a strong association 
between frailty and daily informal care costs was found,20 and 
in the Netherlands, one study showed increased health care 
costs among frail elderly persons.21 In the USA, sarcopenia 
has placed a significant economic burden on government-
reimbursed health care services.7 Also, similar to frailty 
and sarcopenia, osteoporosis has had a high impact on state 
Table 1 Descriptive statistics of participants
Variable All 
(N=689)
Muscle 
weakness 
(n=65)
Normal 
(n=624)
p-valuea
Age, years 75.6 (5.1) 81.8 (6.6) 75.2 (4.8) ,0.001
Age categories
70–74, % 54.0 4.6 95.4 ,0.001
75–79, % 24.4 7.1 92.9
80–84, % 14.8 20.6 79.4
85+, % 6.8 31.9 68.1
Sex
Males, % 44.1 8.6 91.4 0.482
Females, % 55.9 10.1 89.9
grip strength, kg 31.7 (9.4) 17.9 (4.4) 32.4 (9.1) ,0.001
Notes: The values are expressed as mean (sD) for continuous data and percentage 
for categorical data. aPearson χ2 test for qualitative variables, Mann–Whitney U test 
for continuous variables.
Table 2 summary of costs per year divided according to weakness 
status
Variable Muscle 
weakness 
(n=65)
Normal 
strength 
(n=624)
p-valuea
Direct costs, € 475.3 (853.0) 221.6 (364.8) 0.001
Medical care
hospital admission, € 318.2 (863.2) 83.6 (317.0) ,0.001
Medical visits, € 90.9 (63.2) 78.0 (79.3) 0.087
Medications, € 66.3 (71.6) 60.1 (84.5) 0.553
Indirect cost
replacement cost, € 649.9 (851.8) 339.8 (660.3) 0.019
Total cost, € 1,125.3 (1,367.2) 561.4 (762.6) 0.001
Notes: The values are expressed as mean (sD); aMann–Whitney U test.
Table 3 generalized linear regression model for weak individuals
Model Direct cost OR 
(95% Wald CI)
Indirect cost OR 
(95% Wald CI)
Total cost OR 
(95% Wald CI)
Both genders 
combined
2.106  
(1.434–3.092)*
1.080  
(0.763–1.529)
1.510  
(0.972–2.346)
Males 1.426  
(0.803–2.533)
1.033  
(0.605–1.764)
1.312  
(0.684–2.517)
Females 2.747  
(1.643–4.593)*
1.051  
(0.673–1.641)
1.582  
(0.875–2.861)
Notes: Models were adjusted for age and BMI; statistical significance *p,0.05.
Abbreviations: BMI, body mass index; Or, odds ratio.
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medical budgets in the USA,22 as well as in Switzerland23 and 
Germany.24 In the Czech Republic, a report by the Organiza-
tion for Economic Co-operation and Development states that 
diseases of the musculoskeletal system are one of the five 
most burdensome disease groups in the country.25 Moreover, 
reduced handgrip strength alone has been identified as a 
predictor of hospitalization costs.26
Although our results reflect those found in previous 
research carried out in the field, several limitations of our 
study should be taken into account. Firstly, the data were 
extracted from a sociological survey based on a question-
naire. Therefore, the subjectivity of responses may have 
altered their meanings. Even though handgrip strength was 
measured by a standard dynamometer, the technique was not 
fully in line with the recommendations for medical research. 
The SHARE sample also contained a small proportion of 
people who were classified as weak compared to those who 
had normal muscle strength. Moreover, participants in the 
muscle weakness group were older than those in the normal 
strength group. This may have skewed our results. Undoubt-
edly, estimating direct and indirect costs using economic data 
could produce more accurate results; unfortunately, such a 
study has not been done in the Czech Republic.
According to our results, muscle weakness has a signifi-
cant impact on health care expenditure, specifically in relation 
to direct costs. Therefore, despite the potential limitations 
of this study, it is important to consider appropriate inter-
ventions that can be introduced to lower the risk of muscle 
weakness, which can in turn reduce associated health care 
expenditure. Physical activity has previously been identi-
fied as an appropriate intervention for decreasing the risk 
of muscle weakness.27 Therefore, interventions involving 
physical activity may be associated with cost saving. In this 
context, the results of our study should lead to increased 
interest in the implementation of physical activity programs 
for the elderly.
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